SK-NEP-1 Cells

Categories: Kidney cancer cell lines Description: SK-NEP-1 is a human cell line originally derived from a nephroblastoma, also known as Wilms' tumor, a common pediatric renal malignancy. This cell line has been used extensively in preclinical research to study nephroblastoma biology and to evaluate novel therapeutic approaches for treating Wilms' tumor. However, later molecular characterizations revealed that SK-NEP-1 expresses the EWS-FLI1 fusion gene, which is characteristic of Ewing sarcoma, indicating that this cell line is more representative of the Ewing family of tumors rather than Wilms' tumor. This discovery has important implications for interpreting past research that utilized SK-NEP-1, as its biological characteristics align more closely with Ewing sarcoma rather than anaplastic Wilms' tumor. Research involving SK-NEP-1 has shown that it is responsive to chemotherapy agents such as vincristine, which inhibits microtubule polymerization, leading to G2/M phase arrest and apoptosis. Additionally, combination therapies using natural compounds like andrographolide have demonstrated synergistic effects in increasing the cytotoxicity of vincristine on SK-NEP-1 cells, primarily through the PI3K-AKT-p53 signaling pathway. This combination was shown to induce apoptosis in SK-NEP-1 cells, both in vitro and in vivo, making it a promising approach for treating tumors that share the molecular characteristics of SK-NEP-1. SK-NEP-1 is thus a critical model for studying the molecular underpinnings of pediatric renal and Ewing sarcoma tumors and for evaluating the effectiveness of drug combinations aimed at improving therapeutic outcomes in these cancer types. Its use in research has contributed to understanding drug-induced apoptosis and the potential of targeting specific signaling pathways like PI3K-AKT-p53 in cancer therapy. Organism: Human Tissue: Kidney Disease: Wilms tumor Metastatic Site: Pleural effusion Synonyms: SKNEP-1, SKNEP1, SKNEP Age: 25 years Gender: Female Ethnicity: Caucasian Morphology: Epithelial-like Growth Properties: Suspension Citation: SK-NEP-1 (Cytion catalog number 300341) Biosafety Level: 1 Ncbi_ Taxid: 9606.0 Cellosaurus Accession: CVCL_0631 Isoenzymes: PGM3, 1, PGM1, 1-2, ES-D, 1, Me-2, 2, AK-1, 1, GLO-1, 2, G6PD, B, Phenotype Frequency Product: 0.0029 Tumorigenic: Yes, in nude mice. Mutational Profile: p53 mut Karyotype: (P12) hypotriploid to hypertriploid (+A1, +A2, +C, +D, +E, +F, +G) with abnormalities including acrocentric fragments, secondary constrictions and large sub telocentric markers Culture Medium: McCoys 5a, w: 3.0 g/L Glucose, w: stable Glutamine, w: 2.0 mM Sodium pyruvate, w: 2.2 g/L NaHCO3 (Cytion article number 820200a) Supplements: Supplement the medium with 10% FBS Subculturing: Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 5 x 105 cells/ml and keep the cell concentration within the range of 3 x 105 to 1 x 106 cells/ml for optimal growth. Fluid Renewal: 2 to 3 times per week Freeze Medium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Thawing And Culturing Cells: Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks, for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes. Sterility: Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. Safety Precautions: When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments. Warranty: We stand by the promise of delivering products with high cell viability and robust culture performance. To achieve the best results, please make sure you follow the storage and culture instructions detailed in the product information sheet closely. Your adherence to these guidelines is key to success. Subject To Material Transfer Agreements: If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement. Required Product 1: 820200a Required Product 3: 860015.0 Required Product 4: 830100.0